Director/PDMR Share Dealings

January 8, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
it has been notified that Dr. Steven Gillis, Non-Executive Director of the
Company, was recently informed that American Depositary Shares ("ADSs"), as set
out below, were acquired on his account by an independent third party
exercising discretion over dealing decisions. The transactions took place on
the NASDAQ.

      Date of         Number of ADSs    Average price per ADS
    transaction           acquired


  October 30, 2014          127                $196.744

 December 19, 2014          76                 $218.16

Following the above transactions, Dr. Gillis holds 674 ADSs. One ADS is equal
to three ordinary shares of 5 pence each in the Company.

This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)
of the Disclosure and Transparency Rules ("DTRs"). In accordance with 3.1.5(R)
of the DTRs, the information required to be included in this notification was
received by the Company today, January 8, 2015.

For further information please contact:

Investor Relations

Jeff Poulton                            jpoulton@shire.com   +1 781 482 0945

Sarah Elton-Farr                        seltonfarr@shire.com +44 1256 894157

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience,
Gastrointestinal, and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas, such as Ophthalmics.

www.shire.com

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release

www.shire.com